

PROVECTUS BIOPHARMACEUTICALS, INC.  
Form DEF 14A  
April 30, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934**

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

**Provectus Biopharmaceuticals, Inc.**  
**(Name of registrant as specified in its charter)**

**(Name of person(s) filing proxy statement, if other than the registrant)**

Payment of Filing Fee (Check the appropriate box):

☒ No fee required

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11

Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form DEF 14A

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐ Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

10025 Investment Drive, Suite 250

Knoxville, Tennessee 37932

*phone* 866/594-5999

*fax* 866/998-0005

Dear Provectus Stockholders:

You are cordially invited to attend the 2018 Annual Meeting of Stockholders of Provectus Biopharmaceuticals, Inc. (“Provectus”) to be held on Wednesday, June 27, 2018, at 4:00 p.m., Eastern Time, at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tennessee 37902.

We are pleased to present you with our 2018 Proxy Statement. At our 2018 Annual Meeting, stockholders will vote on the matters set forth in the 2018 Proxy Statement and the accompanying notice of this Annual Meeting. Your board of directors has recommended five highly qualified and experienced nominees for election to the board of directors at the 2018 Annual Meeting. Highlights of the detailed information included in the Proxy Statement can be found in the section entitled “Questions and Answers About the 2018 Annual Meeting of Stockholders” starting on page 2, and detailed information regarding the director candidates can be found under “Proposal 1 – Election of Directors” starting on page 21.

We have elected to provide access to our proxy materials over the Internet under the Securities and Exchange Commission’s “notice and access” rules this year. We believe that providing our proxy materials over the Internet increases the ability of our stockholders to connect with the information they need, while reducing the environmental impact of our Annual Meeting and the cost to the Company associated with the physical printing and mailing of proxy materials.

Whether or not you will attend the meeting, we hope that your shares are represented and voted. In advance of the meeting on June 27, 2018, please vote and submit your proxy as soon as possible via the Internet, by telephone, or if you have requested to receive printed proxy materials, by mailing a proxy or voting instruction card enclosed with those materials. Instructions on how to vote are found in the section entitled “Questions and Answers About the 2018 Annual Meeting of Stockholders – How do I vote before the Annual Meeting?” starting on page 3.

For more information and up-to-date postings, please go to our website, [www.provectusbio.com/annualmeeting](http://www.provectusbio.com/annualmeeting).

Thank you for being a stockholder of Provectus.

Sincerely,

Timothy C. Scott, Ph.D.  
President

10025 Investment Drive, Suite 250

Knoxville, Tennessee 37932

*phone 866/594-5999 fax 866/998-0005*

**NOTICE OF 2018 ANNUAL MEETING OF STOCKHOLDERS  
TO BE HELD ON WEDNESDAY, JUNE 27, 2018**

To the Stockholders of Provectus Biopharmaceuticals, Inc.:

NOTICE IS HEREBY GIVEN that we will hold the 2018 Annual Meeting of Stockholders of Provectus Biopharmaceuticals, Inc. on Wednesday, June 27, 2018 at 4:00 p.m. Eastern Time, at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tennessee 37902. The 2018 Annual Meeting is being held for the following purposes:

1. to elect five directors to serve on our board of directors;
2. to conduct an advisory vote to approve the compensation of our named executive officers; and
3. to ratify the selection of Marcum LLP as our independent registered public accounting firm for 2018.

Stockholders also will transact any other business that properly comes before the 2018 Annual Meeting of Stockholders.

**OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” EACH OF THE FIVE DIRECTOR NOMINEES IDENTIFIED IN THE PROXY STATEMENT, AND “FOR” PROPOSALS 2 AND 3.**

Only stockholders of record as of the close of business on April 30, 2018 will be entitled to notice of and to vote at the 2018 Annual Meeting of Stockholders and any adjournment thereof.

We are mailing a Notice of Internet Availability of Proxy Materials (the “Notice”) to many of our stockholders instead of paper copies of our proxy statement and our annual report. The Notice contains instructions on how to access those documents over the Internet. The Notice also contains instructions on how stockholders can receive a paper copy of our proxy materials, including the proxy statement, our 2017 Annual Report and proxy card.

We hope that you will be able to attend the Annual Meeting. We ask, however, whether or not you plan to attend the Annual Meeting that you vote as soon as possible. Promptly voting will help ensure that the greatest number of stockholders are present whether in person or by proxy. You may vote over the Internet, as well as by telephone, or, if you requested to receive printed proxy materials, by mailing a proxy or voting instruction card enclosed with those materials. Please review the instructions on each of your voting options described in the proxy statement, as well as in the Notice you received in the mail.

If you attend the Annual Meeting in person, you may revoke your proxy at the Annual Meeting and vote your shares in person. You may revoke your proxy at any time before the proxy is exercised. Should you desire to revoke your proxy, you may do so as provided in the accompanying proxy statement.

**Important Notice Regarding the Availability of Proxy Materials for the 2018 Annual Meeting of Stockholders to Be Held on Wednesday, June 27, 2018. The Notice of Internet Availability of Proxy Materials, this Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2017 are available at: <http://www.provectusbio.com/annual-reports.html>.**

By order of our board of directors,

Timothy C. Scott, Ph.D.  
President

April 30, 2018

Knoxville, Tennessee

## TABLE OF CONTENTS

<u>QUESTIONS AND ANSWERS ABOUT THE 2018 ANNUAL MEETING OF STOCKHOLDERS</u>	2
<u>STOCK OWNERSHIP</u>	6
<u>CORPORATE GOVERNANCE</u>	8
<u>COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS</u>	11
<u>SUMMARY COMPENSATION TABLE</u>	14
<u>OUTSTANDING EQUITY AWARDS AT 2017 FISCAL YEAR-END</u>	15
<u>EQUITY COMPENSATION PLAN INFORMATION</u>	15
<u>DIRECTOR COMPENSATION</u>	16
<u>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</u>	17
<u>PROPOSAL 1 ELECTION OF DIRECTORS</u>	21
<u>PROPOSAL 2 ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS</u>	24
<u>PROPOSAL 3 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>	25
<u>AUDIT COMMITTEE REPORT</u>	27
<u>OTHER INFORMATION CONCERNING MANAGEMENT</u>	28
<u>OTHER MATTERS</u>	29
<u>ADDITIONAL INFORMATION</u>	30

10025 Investment Drive, Suite 250

Knoxville, Tennessee 37932

*phone 866/594-5999 fax 866/998-0005*

**PROXY STATEMENT FOR**

**2018 ANNUAL MEETING OF STOCKHOLDERS**

**TO BE HELD ON JUNE 27, 2018**

We are delivering these proxy materials to solicit proxies on behalf of the board of directors of Provectus Biopharmaceuticals, Inc., for the 2018 Annual Meeting of Stockholders to be held on Wednesday, June 27, 2018, beginning at 4:00 p.m. Eastern Time, at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tennessee 37902.

We first mailed the Notice of Internet Availability of Proxy Materials to our stockholders on or about April 30, 2018.

We will refer to Provectus Biopharmaceuticals, Inc. and its subsidiaries throughout this Proxy Statement as “we,” “us,” the “Company” or “Provectus.” We will refer to the board of directors as the “Board.”

At the Annual Meeting, our stockholders will vote on proposals:

1. to elect five directors to serve on our Board;
2. to conduct an advisory vote to approve the compensation of our named executive officers; and
3. to ratify the selection of Marcum LLP as our independent registered public accounting firm for 2018.

The proposals are set forth in the accompanying Notice of 2018 Annual Meeting of Stockholders and are described in more detail in this Proxy Statement. Stockholders also will transact any other business, not known or determined at



the time of this proxy solicitation that properly comes before the 2018 Annual Meeting of Stockholders, although our Board knows of no such other business to be presented.

**OUR BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” EACH OF THE FIVE NOMINEES TO OUR BOARD IDENTIFIED IN THE PROXY STATEMENT, AND “FOR” PROPOSALS 2 AND 3.**

When you submit your proxy by executing and returning the enclosed proxy card, you will authorize the proxy holders – Timothy C. Scott, Ph.D. and Eric A. Wachter, Ph.D. – to vote as proxy all your shares of common stock and otherwise to act on your behalf at the 2018 Annual Meeting of Stockholders and any adjournment thereof, in accordance with the instructions set forth therein. These persons also will have discretionary authority to vote your shares on any other business that properly comes before the meeting. They also may vote your shares to adjourn the meeting and will be authorized to vote your shares at any adjournment of the meeting.

## QUESTIONS AND ANSWERS ABOUT THE 2018 ANNUAL MEETING OF STOCKHOLDERS

Why did I receive a one-page notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?

Pursuant to rules adopted by the Securities and Exchange Commission (the “SEC”), the Company will use the Internet as the primary means of furnishing proxy materials to stockholders this year. Accordingly, the Company is sending a Notice of Internet Availability of Proxy Materials (the “Notice”) to the Company’s stockholders. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request a printed set of the complete proxy materials. Instructions on how to access the proxy materials over the Internet or to request a printed copy may be found in the Notice. In addition, stockholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. The Company encourages stockholders to take advantage of the availability of the proxy materials on the Internet to help reduce the environmental impact of its annual meetings and the cost to the Company associated with the physical printing and mailing of materials.

What is the purpose of the 2018 Annual Meeting of Stockholders?

At the 2018 Annual Meeting of Stockholders (the “2018 Annual Meeting”), stockholders will act upon the following matters:

1. To elect five directors to serve on our Board;
2. To conduct an advisory vote to approve the compensation of our named executive officers; and
3. To ratify the selection of Marcum LLP as our independent registered public accounting firm for 2018.

Stockholders also will transact any other business, not known or determined at the time of this proxy solicitation, that properly comes before the 2018 Annual Meeting, although our Board knows of no such other business to be presented.

Who is entitled to vote?

Only stockholders of record at the close of business on April 30, 2018, the record date for the 2018 Annual Meeting, are entitled to receive notice of the 2018 Annual Meeting and to vote the shares of common stock that they held on that date at the 2018 Annual Meeting. Each outstanding share of common stock entitles its holder to cast one vote on each matter to be voted on at the 2018 Annual Meeting.

What constitutes a quorum?

The presence at the 2018 Annual Meeting, in person or by proxy, of the holders of a majority of the shares of common stock outstanding on the record date, April 30, 2018, will constitute a quorum. Shares held by stockholders present at the 2018 Annual Meeting in person or represented by proxy who elect to abstain from voting nonetheless will be included in the calculation of the number of shares considered present at the 2018 Annual Meeting.

As of March 31, 2018, there were 378,888,190 shares of common stock outstanding.

What happens if a quorum is not present at the 2018 Annual Meeting?

If a quorum is not present at the scheduled time of the meeting, the holders of a majority of the shares of common stock present in person or represented by proxy at the meeting may adjourn the meeting to another place, date, or time until a quorum is present. The place, date, and time of the adjourned meeting will be announced when the adjournment is taken, and no other notice will be given unless the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting.

May I vote my shares in person at the Annual Meeting?

Yes. You may vote your shares at the Annual Meeting if you attend in person, even if you previously submitted a proxy card or voted by Internet or telephone. Whether or not you plan to attend the Annual Meeting in person, however, in order to assist us in tabulating votes at the Annual Meeting, we encourage you to vote by using the Internet, telephone, or, if applicable, by returning a proxy card.

How do I vote before the Annual Meeting?

Before the Annual Meeting, you may vote your shares in one of the following three ways:

1. via the Internet by following the instructions provided in the Notice;
2. by mail, if you requested printed copies of the proxy materials, by filling out the form of proxy card and sending it back in the envelope provided; or
3. by telephone, if you requested printed copies of the proxy materials, by calling the toll free number found on the proxy card. If you requested printed copies of the proxy materials, and properly sign and return your proxy card and return it in the prepaid envelope, your shares will be voted as you direct.

Please use only one of the three ways to vote. If you hold shares in the name of a broker, your ability to vote those shares by Internet or telephone depends on the voting procedures used by your broker, as explained below.

How do I vote if my broker holds my shares in “street name”?

If your shares are held in “street name,” your bank or broker will send you the Notice. Many (but not all) brokerage firms and banks participate in a program provided through Broadridge Financial Solutions, Inc. that offers Internet and telephone voting options. If you do not give instructions to your nominee, it will nevertheless be entitled to vote your shares on “discretionary” items but will not be permitted to do so on “non-discretionary” items. Proposals 1 and 2 are non-discretionary items for which a nominee will not have discretion to vote in the absence of voting instructions from you. Proposal 3, however, is a discretionary item on which your nominee will be entitled to vote your shares even in the absence of instructions from you.

Can I change my mind and revoke my proxy?

Yes. To revoke a proxy given pursuant to this solicitation, you must:

sign another proxy with a later date and return it to our Secretary, Provectus Biopharmaceuticals, Inc., 10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932 at or before the Annual Meeting;

provide our Secretary with a written notice of revocation dated later than the date of the proxy at or before the Annual Meeting;

re-vote by using the telephone following the instructions on the proxy card;

re-vote by using the Internet by following the instructions in the Notice; or

attend the Annual Meeting and vote in person—note that attendance at the Annual Meeting will not revoke a proxy if you do not actually vote at the Annual Meeting.

What are the Board's recommendations?

Our Board unanimously recommends that you vote:

1. **"FOR"** the proposal to elect five directors to serve on our Board;
2. **"FOR"** the proposal to approve, on an advisory basis, the compensation of our named executive officers; and
3. **"FOR"** the proposal to ratify the selection of Marcum LLP as our independent registered public accounting firm for 2018.

What happens if I do not specify how my shares are to be voted?

If you sign and return your proxy card or complete the telephone or Internet voting procedures but do not indicate any voting instructions, your shares will be voted **"FOR"** each of the nominees for director identified in Proposal 1 and **"FOR"** Proposals 2 and 3.

Will any other business be conducted at the 2018 Annual Meeting?

As of the date hereof, our Board knows of no business that will be presented at the Annual Meeting other than the proposals described in this Proxy Statement. If any other business is properly brought before the 2018 Annual Meeting, the proxy holders will vote your shares in accordance with their best judgment.

What vote is required to approve each item?

The director nominees will be elected to serve on our Board if they receive a plurality of the votes cast on the shares of common stock present in person or represented by proxy at the 2018 Annual Meeting and entitled to vote on the subject matter. This means that the director nominees will be elected if they receive more votes than any other person at the 2018 Annual Meeting. If you vote to “Withhold Authority” with respect to the election of one or more director nominees, your shares of common stock will not be voted with respect to the person or persons indicated, although they will be counted for the purpose of determining whether there is a quorum at the meeting.

The advisory vote to approve the compensation of our named executive officers will be approved if a majority of the shares of common stock present in person or represented by proxy at the 2018 Annual Meeting and entitled to vote on the subject matter are voted in favor of the proposal.

The selection of Marcum LLP as our independent registered public accounting firm for 2018 will be ratified if a majority of the shares of common stock present in person or represented by proxy at the meeting and entitled to vote on the subject matter are voted in favor of the proposal.

#### How will Abstentions and Broker Non-Votes be Treated?

You do not have the option of abstaining from voting on Proposal 1, but you may abstain from voting on Proposals 2 and 3. With respect to Proposal 1, because the directors are elected by a plurality vote, an abstention will have no effect on the outcome of the vote and, therefore, is not offered as a voting option on the proposal. In the case of an abstention on Proposals 2 and 3, your shares of common stock would be included in the number of shares of common stock considered present at the meeting for the purpose of determining whether there is a quorum. Because your shares of common stock would be voted but not in favor of Proposals 2 and 3, your abstention would have the same effect as a negative vote in determining the outcome of the vote on the proposal.

Broker non-votes occur when a brokerage firm, bank, or other nominee does not vote shares that it holds in “street name” on behalf of the beneficial owner because the beneficial owner has not provided voting instructions to the nominee with respect to a non-discretionary item. Proposals 1 and 2 are non-discretionary items for which a nominee will not have discretion to vote in the absence of voting instructions from you. Proposal 3, however, is a discretionary item on which your nominee will be entitled to vote your shares of common stock even in the absence of instructions from you. Accordingly, it is possible for there to be broker non-votes with respect to Proposals 1 and 2, but there will not be broker non-votes with regard to Proposal 3. In the case of a broker non-vote, your shares of common stock would be included in the number of shares of common stock considered present at the meeting for the purpose of determining whether there is a quorum. A broker non-vote, being shares of common stock not entitled to vote, would not have any effect on the outcome of the vote on Proposals 1 and 2.



## STOCK OWNERSHIP

## Directors, Executive Officers, and Other Stockholders

The following table provides information about the beneficial ownership of common stock as of March 15, 2018, unless otherwise indicated, for each of our directors, each of our executive officers named in the “Summary Compensation Table” of this Proxy Statement and all of our directors and executive officers as a group. We do not believe any person beneficially owns more than 5% of our outstanding common stock. Each outstanding share of common stock entitles its holder to cast one vote on each matter to be voted on at the 2018 Annual Meeting.

<b>Name and Address<sup>(1)</sup></b>	<b>Amount and Nature of Beneficial Ownership<sup>(2)</sup></b>	<b>Percentage of Class<sup>(2) (3)</sup></b>
Directors and Named Executive Officers:		
Ed Pershing, CPA	4,265,480 (4)	1.1 %
Dominic Rodrigues, CFA	1,319,880 (5)	*
Bruce Horowitz	2,442,243 (6)	*
Jan Koe	1,486,300 (7)	*
John Lacey, III, M.D.	100,000 (8)	*
Timothy C. Scott, Ph.D.	3,830,966 (9)	1.0 %
Eric Wachter, Ph.D.	7,199,298 (10)	1.9 %
John Glass, CPA	200,000 (11)	*
All Directors and Executive Officers as a Group (8 Persons)	20,844,167 (12)	5.4 %

\* Less than 1% of the outstanding shares of common stock.

Drs. Lacey, Scott and Wachter, and Messrs. Glass, Horowitz, Koe, Pershing, and Rodrigues are officers and/or (1) directors of Provectus Biopharmaceuticals, Inc., whose business address is 10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932.

Shares of common stock that a person has the right to acquire within 60 days of March 15, 2018 are deemed outstanding for computing the percentage ownership of the person having the right to acquire such shares, but are (2) not deemed outstanding for computing the percentage ownership of any other person. Except as indicated by a note, each stockholder listed in the table has sole voting and investment power as to the shares owned by that person.

(3) As of March 15, 2018, there were 378,888,190 shares of common stock issued and outstanding.

(4)

Mr. Pershing's beneficial ownership includes 60,600 shares of common stock owned by his spouse, 16,500 shares of common stock owned by his spouse through a retirement plan, 3,750 shares of common stock held as custodian for a grandchild, 81,500 shares of common stock owned by Mr. P's Foundation, a nonprofit corporation of which Mr. Pershing is an affiliate, 550,000 shares of common stock owned by Perkins Place, a general partnership of which Mr. Pershing is an affiliate, 27,500 shares of common stock issuable upon the exercise of warrants held by Perkins Place, which are exercisable within 60 days, 705,000 shares of common stock issuable upon the exercise of warrants held by Mr. Pershing, which are exercisable within 60 days, and 1,745,130 shares of common stock owned by Mr. Pershing through a retirement plan. Does not include any shares issuable upon conversion of outstanding principal and accrued but unpaid interest under that certain Secured Convertible Promissory Note, dated April 12, 2018, by the Company in favor of Mr. Pershing in the principal amount of \$200,000.

- Mr. Rodrigues' beneficial ownership includes 509,089 shares of common stock held jointly with his spouse, 112,700 shares of common stock owned by his spouse, 23,700 shares of common stock held as custodian for his children, 242,000 shares of common stock owned by CAL Enterprises LLC, an entity that Mr. Rodrigues controls, 961 shares of common stock issuable upon the exercise of warrants held by CAL Enterprises LLC, which are exercisable within 60 days, 30 shares of common stock issuable upon the exercise of warrants held by Mr. Rodrigues, which are exercisable within 60 days, and 431,400 shares of common stock owned through a retirement plan. Does not include any shares issuable upon conversion of outstanding principal and accrued but unpaid interest under that certain Secured Convertible Promissory Note, dated April 3, 2017, by the Company in favor of CAL Enterprises LLC in the principal amount of \$2.5 million. Mr. Rodrigues disclaims beneficial ownership of the securities held by CAL Enterprises LLC except to the extent of his pecuniary interest therein.
- (5) Mr. Horowitz's beneficial ownership includes 50,000 shares of common stock owned by his spouse, 1,000,000 shares of common stock issuable upon the exercise of warrants, which are exercisable within 60 days, and 325,000 shares of common stock owned through a retirement plan.
- Mr. Koe's beneficial ownership includes 200,000 shares of common stock subject to options which are exercisable within 60 days, 150,000 shares of common stock held by Vekoe Partners LLC, of which Mr. Koe is an affiliate, and 350,000 shares of common stock issuable upon the exercise of warrants, which are exercisable within 60 days.
- (7) Dr. Lacey's beneficial ownership includes 20,000 shares of common stock held jointly with his spouse and 80,000 shares held through a retirement account.
- (8) Dr. Scott's beneficial ownership includes 503,125 shares of common stock held in a 401(k) plan, and 1,750,000 shares of common stock subject to options which are exercisable within 60 days. Dr. Scott pledged 1,000,000 shares of his common stock pursuant to that certain Stock Pledge Agreement, dated October 3, 2014, between Dr. Scott and the Company in order to secure Dr. Scott's obligations under that certain Stipulated Settlement Agreement and Mutual Release between the Company and Dr. Scott, dated June 6, 2014. Does not include any shares issuable upon conversion of outstanding principal and accrued but unpaid interest under a certain Secured Convertible Promissory Note, dated February 21, 2018, by the Company in favor of Dr. Timothy Scott in the principal amount of \$250,000.
- (9) Dr. Wachter's beneficial ownership includes 4,867 shares of common stock held by the Eric A. Wachter 1998 Charitable Remainder Unitrust, 930,248 shares of common stock held in a 401(k) plan, and 550,000 shares of common stock subject to options which are exercisable within 60 days. Does not include any shares issuable upon conversion of outstanding principal and accrued but unpaid interest under that certain Amended and Restated Secured Convertible Promissory Note, dated April 3, 2017, by the Company in favor of Dr. Wachter in the outstanding principal amount of \$2.5 million, and any shares issuable upon conversion of outstanding principal and accrued but unpaid interest under that certain Secured Convertible Promissory Note, dated January 25, 2018, by the Company in favor of Dr. Wachter in the principal amount of \$500,000. Dr. Wachter pledged 1,000,000 shares of his common stock pursuant to that certain Stock Pledge Agreement, dated October 3, 2014, between Dr. Wachter and the Company in order to secure Dr. Wachter's obligations under that certain Stipulated Settlement Agreement and Mutual Release between the Company and Dr. Wachter, dated June 6, 2014.
- (10) Mr. Glass's beneficial ownership includes 200,000 shares of common stock held jointly with his spouse.
- (11) Includes 4,583,491 shares of common stock subject to options and warrants which are exercisable within 60 days.
- (12)

Section 16(a) Beneficial Ownership Reporting Compliance

The federal securities laws require our directors and executive officers and persons who beneficially own more than 10% of a registered class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our securities. Based solely on our review of the copies of these forms received by us or representations from reporting persons, we believe that SEC beneficial ownership reporting requirements for 2017 were met.

## CORPORATE GOVERNANCE

### Board Leadership Structure

Our Board currently consists of five members, Bruce Horowitz, Jan Koe, John Lacey, III, M.D., Ed Pershing, CPA, and Dominic Rodrigues, CFA. Alfred E. Smith, IV and Kelly M. McMasters, M.D. resigned from our Board effective as of April 3, 2017, in connection with the election of Messrs. Horowitz and Rodrigues to the Board, at which time the number of seats and the number of directors on our Board was reduced from five to four. Effective April 27, 2018, Eric Wachter, Ph.D. stepped down from our Board, and the Board increased the number of seats and the number of directors on our Board from four to five. Dr. Lacey and Mr. Pershing were elected to fill the two vacancies on the Board resulting from Dr. Wachter's resignation from the Board and the increase in the number of directors. Mr. Pershing serves as non-executive Chairman of our Board and Mr. Rodrigues serves as non-executive Vice Chairman effective April 27, 2018. Mr. Rodrigues served as our non-executive Chairman from April 3, 2017 to April 27, 2018.

Four members of our Board, Dr. Lacey and Messrs. Koe, Pershing and Rodrigues, are considered independent under the independence standards of the NYSE American LLC. Mr. Smith and Dr. McMasters were considered independent under the independence standards of the NYSE MKT (now known as the NYSE American LLC) until their resignations from the Board in April 2017. Effective May 1, 2017, NYSE MKT removed from listing our common stock and class of listed warrants, which continue to trade on the OTCQB.

We believe that it is appropriate to separate the positions of Chairman and Chief Executive Officer to ensure that the appropriate level of independent oversight is applied to all management decisions and avoids any potential conflicts of interest. The Company also does not currently have a Chief Executive Officer, although our President, Dr. Scott, serves as our principal executive officer. Our entire board of directors is responsible for our risk oversight function due to the fact that we have only two employees and independent contractors serving as our interim Chief Financial Officer and chief operations consultant, among other roles.

### Board and Committees

Our Board met five times and took action by unanimous written consent seven times during 2017. Each incumbent director attended all meetings of our Board and its committees on which he served during 2017. Members of our Board are encouraged to attend the 2018 Annual Meeting. Directors Horowitz and Rodrigues and former Director Wachter attended the 2017 Annual Meeting of Stockholders in person, and Director Koe attended this meeting via telephone.

We have three standing Board committees: the audit committee, the compensation committee, and the corporate governance and nominating committee (the “nominating committee”).

#### Audit Committee

The audit committee consists of Dr. Lacey and Messrs. Horowitz, Koe, Pershing and Rodrigues. Dr. Lacey and Messrs. Koe, Pershing and Rodrigues are independent directors under the listing standards of the NYSE American LLC. Mr. Pershing is the chairman of the audit committee. Our Board has determined that Messrs. Pershing and Rodrigues qualify as “audit committee financial experts,” as defined under the rules of the SEC. The audit committee met four times during 2017.

The audit committee's responsibilities include:

1. Hiring one or more independent registered public accountants to audit our books, records and financial statements and to review our systems of accounting (including our systems of internal control);
2. Discussing with the independent registered public accounting firm the results of the annual audit and quarterly reviews;
3. Conducting periodic independent reviews of the systems of accounting (including systems of internal control);
4. Making reports periodically to our Board with respect to its findings; and
5. Undertaking other activities described more fully in the section called "Audit Committee Report."

Our audit committee charter is posted on our website under the "Investors" subpage, at <http://provectusbio.com/media/docs/AuditCommitteeCharter.pdf>, and is also available in print to any stockholder or other interested party who makes such a request to the Company's Secretary. The information on our website, however, is not a part of this Proxy Statement.

#### Compensation Committee

The compensation committee consists of Dr. Lacey and Messrs. Horowitz, Koe, Pershing and Rodrigues. Dr. Lacey and Messrs. Koe, Pershing and Rodrigues are independent directors under the listing standards of the NYSE American LLC. Mr. Koe is the chairman of the compensation committee. The compensation committee met three times during 2017.

The compensation committee's responsibilities include:

1. Reviewing and approving annually the corporate goals and objectives relevant to each executive officer, and at least annually, evaluating each executive officer's performance in light of these goals and objectives, and setting each executive officer's compensation, including salary, bonus and incentive compensation, based on this evaluation;
2. Reviewing our compensation and benefits plans;
3. Reviewing and recommending to the entire Board the compensation for members of our Board; and

4. Other matters that our Board specifically delegates to the compensation committee from time to time.

Our compensation committee charter is posted on our website under the “Investors” subpage, at <http://provectusbio.com/media/docs/CompensationCommitteeCharter.pdf>, and is also available in print to any stockholder or other interested party who makes such a request to the Company’s Secretary. The information on our website, however, is not a part of this Proxy Statement.



## Nominating Committee and Director Nominations

The nominating committee consists of Dr. Lacey and Messrs. Horowitz, Koe, Pershing and Rodrigues. Dr. Lacey and Messrs. Koe, Pershing and Rodrigues are independent directors under the listing standards of the NYSE American LLC. Dr. Lacey is the chairman of the nominating committee. The nominating committee did not hold any meetings during 2017.

Our Board adopted a written charter for our nominating committee, which is available to our stockholders and other interested parties on our website under the “Investors” subpage, at <http://provectusbio.com/media/docs/NominatingCommitteeCharter.pdf>, and is also available in print to any stockholder or other interested party who makes such a request to the Company’s Secretary. The information on our website, however, is not a part of this Proxy Statement.

The nominating committee’s responsibilities include:

1. Assisting our Board to identify and approve the nomination of individuals qualified to serve as members of our Board;
2. Reviewing the qualifications and performance of incumbent directors to determine whether to recommend them as nominees for re-election;
3. Developing and recommending to our Board corporate governance policies for the Company;
4. Reviewing periodically the management succession plan of the Company, and formally recommending to our Board, as needed, successors to departing executive officers if a vacancy occurs; and
5. Evaluating the performance of our Board.

Our nominating committee has no set procedures or policy on the selection of nominees or evaluation of stockholder recommendations and will consider these issues on a case-by-case basis. Our nominating committee will consider stockholder recommendations for director nominees that are properly received in accordance with our bylaws and the applicable rules and regulations of the SEC. Our nominating committee screens all potential candidates in the same manner. Our nominating committee’s review will typically be based on all information provided with respect to the potential candidate. Our nominating committee has not established specific minimum qualifications that must be met by a nominee for a position on our Board or specific qualities and skills for a director. Our nominating committee may consider the diversity of qualities and skills of a nominee, but our nominating committee has no formal policy in this regard. For more information, please see the section below entitled “ADDITIONAL INFORMATION.”

Stockholders who wish to contact the members of our Board may do so by sending an e-mail addressed to them at [info@provectusbio.com](mailto:info@provectusbio.com).

## COMPENSATION Of Directors and Executive Officers

Because we are a smaller reporting company, we are not required to include a Compensation Discussion and Analysis section in this Proxy Statement and have elected to comply with the scaled-down executive compensation disclosure requirements applicable to smaller reporting companies.

### Base Salary and Employment Agreements

On April 28, 2014, we entered into amended and restated executive employment agreements with Drs. Scott and Wachter to serve as our President and Chief Technology Officer, respectively. Each agreement provides that such executive will be employed for a five-year term with automatic one-year renewals unless previously terminated pursuant to the terms of the agreement or either party gives notice that the term will not be extended. Each executive officer's base salary is \$500,000 per year and any increase to such base salary will be determined by the compensation committee in its sole discretion. The Company and Drs. Scott and Wachter are parties to a Stipulated Settlement Agreement dated June 6, 2014 (the "Kleba Settlement Agreement") that was negotiated to resolve certain claims asserted against Drs. Scott and Wachter derivatively, pursuant to which each of Drs. Scott and Wachter agreed to repay the Company compensation that was paid to such executive along with legal fees and other expenses incurred by the Company. Each of Drs. Scott and Wachter have \$200,000 withheld from their salary each year until such repayment is satisfied. Named executive officers are entitled to reimbursement for all reasonable out-of-pocket expenses incurred during their performance of services under the agreements.

The employment agreements for Drs. Scott and Wachter generally provide that in the event that the executive's employment is terminated (i) voluntarily by the executive without Good Reason (as defined in the respective employment agreement) or (ii) by the Company "for cause" (as defined in the respective employment agreement), the Company will pay the executive's compensation only through the last day of the employment period and, except as may otherwise be expressly provided, the Company will have no further obligation to the executive. In the event that the executive's employment is terminated by the Company other than "for cause" (including death or disability), or if the executive voluntarily resigns for Good Reason, for so long as the executive is not in breach of his continuing obligations under the non-competition, non-solicitation and confidentiality restrictions contained in such executive's employment agreement, the Company will continue to pay the executive (or his estate) an amount equal to his base salary in effect immediately prior to the termination of his employment for a period of 24 months, to be paid in accordance with the Company's regular payroll practices through the end of the fiscal year in which termination occurs and then in one lump sum payable to the executive in the first month of the fiscal year following termination, as well as any prorated bonuses based upon the bonuses paid with regard to the prior fiscal year, plus benefits on a substantially equivalent basis to those which would have been provided to the executive in accordance with the terms of such benefit plans.

The employment agreements for our named executive officers also include non-competition, non-solicitation and confidentiality obligations.

## Independent Contractor Agreements

During 2016, the Company entered into an independent contractor agreement, as amended (the “Glass Agreement”), with Mr. Glass, pursuant to which he serves as interim chief financial officer of the Company and performs duties and services consistent with the position of chief financial officer for a public company. The Glass Agreement provides that, in consideration for such services, Mr. Glass will be paid \$125 per hour. Mr. Glass is also entitled to a \$20,000 cash bonus payment on each of January 1, April 1, June 1, and September 1, 2017 (or the first business day thereafter) so long as he is serving as interim chief financial officer on such date. The Glass Agreement further provides that, following the termination of the Glass Agreement by the Company as a result of the hiring of a permanent chief financial officer, Mr. Glass will also be entitled to a severance payment of \$20,000 subject to certain terms and conditions set forth in the Glass Agreement. Under the Glass Agreement, the Company will provide Mr. Glass with a per diem for meals on the days when he is rendering services and will reimburse Mr. Glass for all reasonable and necessary expenses relating to his provision of services under the Glass Agreement. The Company also agreed to indemnify Mr. Glass for claims made against him based upon the performance of his services and to have him named as an additional named insured under the Company’s general liability and directors and officers liability insurance policies. The Glass Agreement remains in effect on a month to month basis unless terminated by either party upon 60 days prior written notice.

During 2017, the Company entered into an independent contractor agreement, as amended (the “Horowitz Agreement”), with Mr. Horowitz, pursuant to which he serves as the primary business operations consultant of the Company and performs duties and services including but not limited to designing and implementing new business strategies and plans, and operating processes and procedures; establishing policies to promote a new company culture; overseeing company operations and the work of executives, managers, and staff members; prioritizing and continuing the Company’s search for a Chief Medical Officer and a new Chief Executive Officer; assisting in fundraising activities; and managing certain partner and vendor relationships. In consideration for such services, Mr. Horowitz will be paid \$125 per hour, up to a maximum of \$20,000 in a calendar month. The Company will reimburse Mr. Horowitz for all reasonable and necessary expenses relating to his provision of services under the Horowitz Agreement. The initial term of the Horowitz Agreement was from April 1, 2017 to June 30, 2017, and thereafter continues on a month-to-month basis unless terminated by either party upon 30 days prior written notice. The Company agreed to indemnify Mr. Horowitz and Capital Strategists, LLC for claims made against him based upon the performance of his services. The Horowitz Agreement contains customary confidentiality, customer non-solicitation, and employee non-solicitation provisions.

## Bonus Awards

No cash bonuses were awarded to named executive officers in 2017 other than to Mr. Glass pursuant to the terms of the Glass Agreement.

401(k) Profit Sharing Plan and Other Benefits

Drs. Scott and Wachter participate in our 401(k) Profit Sharing Plan, which was formed in 2010. Contributions to the 401(k) Profit Sharing Plan by us are discretionary. Through 2016, we contributed the maximum amount permitted to be contributed by us with regard to each executive officer pursuant to our 401(k) plan, regardless of the amount, if any, contributed by the respective executive officers. Contributions by us in 2016 totaled \$159,000. The Company made no contributions in 2017. We will match the 401(k) contributions of each executive officer participating in our 401(k) plan in an amount equal to such executive officer's own contribution, up to an amount equal to half of the maximum amount we are permitted to contribute. We maintain broad-based benefits that are provided to all employees, including health insurance, life and disability insurance, dental insurance, and a vacation policy that requires a minimum amount of vacation time used but provides for cash compensation in lieu of vacation taken if appropriate. Executive officers receive a total of six weeks per year and a cash payment for accrued but unused vacation of up to two weeks per year.

## Long-Term Incentives

At the 2014 annual meeting of stockholders, our stockholders approved the Provectus Biopharmaceuticals, Inc. 2014 Equity Compensation Plan (the “2014 Equity Compensation Plan”), which authorizes our Board to grant options that qualify as “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986 (the “Code”), and options that do not qualify as incentive stock options under the Code (“non-qualified stock options,” and collectively with incentive stock options, “options”). We are authorized to grant options under the 2014 Equity Compensation Plan for up to 20,000,000 shares of our common stock. If any options granted under the 2014 Equity Compensation Plan are forfeited or terminated for any reason, the shares of common stock that were subject to the options will again be available for future distribution under the 2014 Equity Compensation Plan. In June 2016, the compensation committee approved an amendment to our 2014 Equity Compensation Plan to allow for restricted stock awards to non-employee directors. Our stockholders approved this amendment at our 2017 annual stockholder meeting.

Under the terms of our 2014 Equity Compensation Plan, prior to the occurrence of a change in control (as defined in the 2014 Equity Compensation Plan), and unless otherwise determined by our Board, any stock options outstanding on the date such change in control is determined to have occurred that are not yet exercisable and vested on such date will become fully exercisable and vested. As of December 31, 2017, the named executive officers had no outstanding unvested stock options. No options were awarded to named executive officers or directors in 2017.

## SUMMARY COMPENSATION TABLE

The table below shows the compensation for services in all capacities we paid during the years ended December 31, 2017 and 2016 to our principal executive officer and our two other executive officers during 2017 (whom we refer to collectively as our “named executive officers”):

<b>Name and Principal Position<sup>(1)</sup></b>	<b>Year</b>	<b>Salary</b>	<b>Bonus</b>	<b>All Other Compensation<sup>(2)</sup></b>	<b>Total</b>
Timothy Scott, Ph.D., President	2017	\$ 300,000 <sup>(3)</sup>	—	\$ 29,490	\$329,490
	2016	\$ 300,000 <sup>(3)</sup>	—	\$ 110,234	\$410,234
Eric Wachter, Ph.D., Chief Technology Officer	2017	\$ 300,000 <sup>(3)</sup>	—	\$ 30,746	\$330,746
	2016	\$ 300,000 <sup>(3)</sup>	—	\$ 110,692	\$410,692
John Glass, CPA, Interim Chief Financial Officer	2017	\$276,534	\$60,000 <sup>(4)</sup>	—	\$336,534
	2016	\$138,500	\$20,000	—	\$158,500

As of December 31, 2017, we had three executive officers: Dr. Scott, our President (principal executive officer), (1) Mr. Glass, our Interim Chief Financial Officer (principal financial officer), and Dr. Wachter, our Chief Technology Officer.

(2) Amounts in this column for 2017 are comprised of the following: unused vacation that was accrued totaling \$19,231 for Dr. Wachter; and health/vision, life, short term disability, and long term disability insurance premiums.

(3) This amount reflects the annual base salary for Drs. Scott and Wachter for 2017 and 2016 after \$200,000 per year for these years was withheld from their respective salaries in connection with the Kleba Settlement Agreement.

Pursuant to the Glass Agreement, Mr. Glass is entitled to a \$20,000 cash bonus payment on each of April 1, June 1, and September 1, 2017 (or the first business day thereafter). The Company has paid Mr. Glass his bonus due on (4) January 1, 2017 and April 1, 2017 and has accrued but not yet paid to Mr. Glass the \$20,000 bonus payments due on June 1, 2017 and September 1, 2017.



## OUTSTANDING EQUITY AWARDS AT 2017 FISCAL YEAR-END

The following table shows the number of equity awards outstanding as of December 31, 2017 for our named executive officers. All the options were exercisable as of December 31, 2017.

Name	Option Awards Number of Shares of Common Stock Underlying Unexercised Options Exercisable (#)			Option Expiration Date
	Option Exercise Price (\$)			
Timothy Scott, Ph.D.	50,000	\$ 1.00		6/27/2018
	50,000	\$ 1.04		6/19/2019
	50,000	\$ 1.16		6/18/2020
	525,000 <sup>(1)</sup>	\$ 1.00		7/22/2020
	50,000	\$ 1.04		7/6/2021
	525,000 <sup>(1)</sup>	\$ 0.93		9/6/2021
	50,000	\$ 0.84		6/28/2022
	50,000	\$ 0.67		8/19/2023
	400,000	\$ 0.75		12/9/2025
Eric Wachter, Ph.D.	50,000	\$ 1.04		6/19/2019
	50,000	\$ 1.16		6/18/2020
	50,000	\$ 1.04		7/6/2021
	400,000	\$ 0.75		12/9/2025
John Glass	—	—		—

(1) Pursuant to the Kleba Settlement Agreement, Dr. Scott agreed to retain incentive stock options for 100,000 shares but forfeited 50% of the nonqualified stock options granted to him in both 2010 and 2011. The amounts set forth in the table reflect the outstanding options after rescission of 50% of the nonqualified stock options granted to Dr. Scott in 2010 and 2011.

## EQUITY COMPENSATION PLAN INFORMATION

The following table summarizes share and exercise price information about our equity compensation plans as of December 31, 2017:

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans <sup>(1)</sup>
Equity compensation plans approved by security holders	4,600,000	\$ 0.94	18,900,000
Equity compensation plans not approved by security holders	—	—	—
Total	4,600,000	\$ 0.94	18,900,000

(1) This amount represents shares of common stock available for issuance under the 2014 Equity Compensation Plan as of December 31, 2017. Awards available for grant under the 2014 Equity Compensation Plan include stock options, stock appreciation rights, restricted stock, long-term performance awards and other forms of equity awards.

## DIRECTOR COMPENSATION

Effective beginning April 2017, each non-employee director receives an annual retainer equal to \$40,000 in cash as compensation for service as a member of the Board. Non-employee directors serving as members of our audit committee will receive \$15,000 per year; the audit committee chairperson will receive \$15,000 per year. Non-employee directors serving as members of our corporate governance and nominating committee will receive \$10,000 per year; the corporate governance and nominating committee chairperson will receive \$15,000 per year. Non-employee directors serving as members of our compensation committee will receive \$10,000 per year; the compensation committee chairperson will receive \$15,000 per year. Our employee directors are compensated for their service as executive officers and are not separately compensated for their service as directors. Each of our directors is also reimbursed for expenses incurred in fulfilling his duties as a director, including attending meetings.

## Director Compensation Table for 2017

Name <sup>(1)</sup>	Fees Paid in Cash	Option Awards <sup>(2)</sup>	All Other Compensation	Total
Bruce Horowitz	\$74,167 <sup>(3)</sup>	—	—	\$74,167
Jan Koe	\$37,500 <sup>(4)</sup>	—	—	\$37,500
Kelly McMasters, M.D. <sup>(5)</sup>	\$0	—	—	\$0
Dominic Rodrigues, CFA	\$55,417 <sup>(4)</sup>	—	—	\$55,417
Alfred E. Smith, IV <sup>(5)</sup>	\$0	—	—	\$0

Two of our directors in 2017 were also full-time employees (Drs. Scott and Wachter), whose compensation is discussed above under the headings “Compensation of Directors and Executive Officers” and “Summary Compensation Table.” Dr. Scott ceased serving as a director effective April 3, 2017, and Dr. Wachter ceased serving as a director effective April 27, 2018.

No stock options or restricted stock awards were granted to directors in 2017. As of December 31, 2017, Mr. Koe<sup>(2)</sup> had a total of 200,000 stock options outstanding, Dr. McMasters had a total of 400,000 stock options outstanding, and Mr. Smith had a total of 250,000 stock options outstanding.

<sup>(3)</sup>Includes \$18,750 in director fees pre-paid in 2017 for 2018 board service.

<sup>(4)</sup>Messrs. Koe and Rodrigues accrued their director fees of \$37,500 and \$55,417, respectively, in 2017.

<sup>(5)</sup>Dr. McMasters and Mr. Smith ceased serving as directors effective April 3, 2017.

## CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

### Policies and Procedures for Related Person Transactions

We have adopted a written related person transactions policy, pursuant to which our executive officers, directors and principal stockholders, including their immediate family members, are not permitted to enter into a related person transaction with us without the consent of our audit committee. Any request for us to enter into a transaction with an executive officer, director, principal stockholder or any of such persons' immediate family members, other than transactions available to all employees generally or involving less than \$10,000 when aggregated with similar transactions, must be presented to our audit committee for review, consideration and approval, unless the transaction involves an employment or other compensatory arrangement approved by the compensation committee. All of our directors, executive officers and employees are required to report to our audit committee any such related person transaction. In approving or rejecting the proposed agreement, our audit committee will take into account, among other factors it deems appropriate, whether the proposed related person transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances, the extent of the person's interest in the transaction and, if applicable, the impact on a director's independence. After consideration of these and other factors, the audit committee may approve or reject the transaction. Consistent with the policy, if we should discover related person transactions that have not been approved, the audit committee will be notified and will determine the appropriate action, including ratification, rescission or amendment of the transaction.

### Related Party Transactions

#### *Convertible Promissory Note*

On February 21, 2017, the Company issued a convertible promissory note in favor of Dr. Wachter, evidencing an unsecured loan from Dr. Wachter to the Company in the original principal amount of up to \$2,500,000 (the "Wachter Note"). Interest accrues on the outstanding balance of the Wachter Note at six percent (6%) per annum calculated on a 360-day basis. As of March 29, 2017, the Company has borrowed the entire \$2,500,000 principal amount under the Wachter Note.

The Wachter Note was amended and restated on April 3, 2017. See "First Tranche of 2017 Financing" below.

#### *First Tranche of 2017 Financing*

On March 23, 2017, the Company entered into an exclusive Definitive Financing Commitment Term Sheet effective as of March 19, 2017 (the “Term Sheet”), which sets forth the terms on which the PRH Group will provide financing to the Company. As described in the Term Sheet, the 2017 Financing from the PRH Group is in the form of a loan (the “Loan”) that is evidenced by secured convertible promissory notes (individually a “PRH Note” and collectively, the “PRH Notes”).

In connection with the funding of the First Tranche, as described in the Term Sheet, the Company, on April 3, 2017, entered into a PRH Note with Cal Enterprises LLC, a Nevada limited liability company, an affiliate of Mr. Rodrigues (the “Rodrigues Note”), in the principal amount of \$2.5 million. In addition, Dr. Wachter amended and restated his promissory note from the Company in the principal amount of \$2.5 million in order to match the terms of the Wachter Note to the PRH Notes. In addition to the customary provisions, each of the Rodrigues Note and the Wachter Note contains the following provisions:

- (i) They are secured on a *pari passu* basis by a first priority security interest on the Company's U.S. intellectual property;
- (ii) They bear interest at the rate of eight percent (8%) per annum on the outstanding principal amount;

- In the event there is a change of control of the Board as proposed by any person or group other than the PRH Group or Dr. Wachter (the "Lenders"), the term of each of the Wachter Note and the Rodrigues Note will be accelerated and all amounts due under the Wachter Note and the Rodrigues Note will be immediately due and
- (iii) payable, plus interest at the rate of eight percent (8%) per annum, plus a penalty in the amount equal to ten times (10x) the outstanding principal amount of the Wachter Note and the Rodrigues Note that has been funded to the Company;

- The outstanding principal amount and interest payable under the Notes is convertible at the sole discretion of the
- (iv) Lenders into shares of the Company's Series D Preferred Stock, a new series of preferred stock to be designated by the Board, at a price per share equal to \$0.2862; and

- Notwithstanding (iv) above, the principal amount of the Notes and the interest payable thereunder will
- (v) automatically convert into shares of the Company's Series D Preferred Stock at a price per share equal to \$0.2862 effective on the 18-month anniversary of the funding of the final tranche of the 2017 Financing, subject to certain exceptions.

The Series D Preferred Stock have not been designated by the Board. As a result, the PRH Notes are not yet convertible into Series D Preferred Stock.

As of March 29, 2017, the Company has drawn down the entire amount of \$2.5 million of the Wachter Note. As of October 31, 2017, the Company has drawn down the entire amount of \$2.5 million of the Rodrigues Note. On January 25, 2018, the Company issued a secured convertible promissory note in favor of Dr. Wachter in the original principal amount of \$500,000 ("the Second Wachter Note"). The terms of the Second Wachter Note, including the terms of its payment and the conditions under which it may be accelerated, are substantially identical to the terms of the notes the Company issued to the PRH Group pursuant to the Term Sheet.

#### *Second Tranche of 2017 Financing*

The PRH Group arranged for the Second Tranche of Financing in the amount of \$5,000,000.

#### *Scott Convertible Promissory Note*

On February 23, 2018, the Company issued a secured convertible promissory note in favor of Dr. Scott in the original principal amount of \$250,000 (the “Scott PRH Note”). The terms of the Scott PRH Note are substantially identical to the terms of the PRH Notes.

*Pershing Convertible Promissory Note*

On April 12, 2018, the Company issued a secured convertible promissory note in favor of Mr. Pershing in the original principal amount of \$200,000 (the “Pershing PRH Note”). The terms of the Pershing PRH Note are substantially identical to the terms of the PRH Notes.

### *Independent Contractor Payments*

During the years ended December 31, 2017 and 2016, the Company paid Bruce Horowitz (Capital Strategists) \$180,000 and \$290,000, respectively, and in 2016 also issued 50,000 shares of the Company's common stock, valued at \$19,500, to Mr. Horowitz for services rendered. Also in 2017, Mr. Horowitz received \$74,167 for director fees. In addition, in 2016, Mr. Horowitz exercised 400,000 warrants to purchase shares of the company's common stock as part of the Company's warrant exchange offer and received 400,000 replacement warrants at an exercise price of \$0.85 per share.

### *Dees Collection Lawsuit*

On May 5, 2016, the Company filed a lawsuit (the "Dees Collection Lawsuit") in the United States District Court for the Eastern District of Tennessee at Knoxville (the "Court") against H. Craig Dees, the Company's former Chairman and Chief Executive Officer, and his wife, Virginia Godfrey (together with Dees, the "Defendants"). The Company alleged that between 2013 and 2015, Dees received approximately \$2.4 million in advanced or reimbursed travel and entertainment expenses from the Company and that Dees did not use these funds for legitimate travel and entertainment expenses as he requested and the Company intended. Instead, the Company alleged that Dees created false receipts and documentation for the expenses and applied the funds to personal use. The Company and Dees are parties to the Kleba Settlement Agreement that was negotiated to resolve certain claims asserted against Dees derivatively. Pursuant to the terms of the Kleba Settlement Agreement, Dees agreed to repay the Company compensation that was paid to him along with legal fees and other expenses incurred by the Company. As of the date of his resignation, Dees still owed the Company \$2,267,750 under the Kleba Settlement Agreement. Dees failed to make such payment, and the Company notified him that he is in default and demanded payment in full. Therefore, the Company alleged counts of conversion, fraud, breach of fiduciary duty, breach of contract, breach of the Kleba Settlement Agreement, unjust enrichment and punitive damages in this lawsuit. The Company also sought foreclosure of the Company's first-priority security interest in the 1,000,000 shares of common stock granted by Dees to the Company as collateral pursuant to that certain Stock Pledge Agreement dated October 3, 2014, between Dees and the Company in order to secure Dees' obligations under the Kleba Settlement Agreement. The Court entered a default judgment against the Defendants on July 20, 2016. On March 15, 2017, the Court granted Ms. Godfrey's motion to set aside the default judgment against her and set a deadline of March 30, 2017 for Ms. Godfrey to file an answer to the Company's complaint. Ms. Godfrey filed her answer on March 28, 2017 demanding that the complaint against her be dismissed. The Court held a hearing on April 26, 2017 to determine damages with respect to the motion for default judgment against Dees. On July 25, 2017, the Court issued a Memorandum Opinion finding that the Company is entitled to receive total damages in the amount of \$6,027,652, comprising compensatory damages for misappropriation of travel and expense funds, compensatory damages for Dees' breach of the Kleba Settlement Agreement, and punitive damages, plus costs. There can be no assurance, however, that the Company will be able to recover any or all of the damages awarded to the Company. The Court also entered a permanent injunction enjoining Dees from selling or dissipating assets until the judgment against him is satisfied. On September 1, 2017, the Company filed a motion with the Court to appoint a receiver to sell 1,000,000 shares of the Company's common stock held by Dees and pledged as security pursuant to the Kleba Settlement Agreement, and to remit the proceeds of this sale to the Company. On November 8, 2017, the Court granted the Company's motion to return 1,497,859 shares of



Company common stock held by Dees. The Court also appointed a receiver to undertake the disposition of such stock in a commercially reasonable manner and remit all funds received pursuant to such sale(s) to the Company, less reasonable costs and expenses incurred as a result of serving as the receiver. On November 21, 2017, the Company entered into a settlement agreement with Ms. Godfrey, which provides for the settlement and release of all claims against Ms. Godfrey in connection with the Dees Collection Lawsuit, and the payment of \$20,000 by Ms. Godfrey to the Company.

*Culpepper Travel Expenses and Related Collection Efforts*

On December 27, 2016, the then Board unanimously voted to terminate Peter Culpepper, effective immediately, from all positions he held with the Company and each of its subsidiaries, including interim Chief Executive Officer and Chief Operating Officer of the Company, “for cause”, in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the “Culpepper Employment Agreement”) based on the results of the investigation conducted by the Audit Committee of the then Board regarding improper expense reimbursements to Culpepper.

The Audit Committee retained independent counsel and an advisory firm with forensic accounting expertise to assist the Audit Committee in conducting the investigation. The Audit Committee found that Culpepper received \$294,255 in expense reimbursements that were unsubstantiated or otherwise improper. The Company seeks to recover from Culpepper the entire \$294,255 in expense reimbursements, as well as all attorney’s fees and auditors’/experts’ fees incurred by the Company in connection with the examination of his expense reimbursements. On December 12, 2017, Culpepper agreed to an order by the SEC to pay disgorgement of \$140,115, prejudgment interest of \$12,261, for a total of \$152,376, to the Company within 30 days. The Company received the payment of \$152,376 in January 2018.

The Company takes the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination “for cause” as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Kleba Settlement Agreement such that the total \$2,240,000 owed by Culpepper pursuant to the Kleba Settlement Agreement plus Culpepper’s proportionate share of the litigation cost in the amount of \$227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of \$2,051,083 as of March 31, 2018 and December 31, 2017, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Kleba Settlement Agreement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Kleba Settlement Agreement), while the Company pursues collection of this amount.

Culpepper disputes that he was terminated “for cause” under the Culpepper Employment Agreement. Pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute on June 28, 2017. Having reached no resolution during the mediation, the parties are proceeding to arbitration under the commercial rules of the American Arbitration Association, which will include, among other claims, both Culpepper’s claim for severance against Provectus and Provectus’ claims against Culpepper for improper expense reimbursements and amounts Culpepper owes Provectus under the Kleba Settlement Agreement.

Other than as set forth above, we had no transactions during 2016 or 2017 that would be required to be disclosed under Item 404(a) of Regulation S-K, and no such transactions are currently proposed for 2018.

PROPOSAL 1  
ELECTION OF DIRECTORS

Director Nominees

The persons listed below have been nominated by our Board to serve as directors for a one-year term expiring at the annual meeting of stockholders occurring in 2019. Each nominee has consented to serve on our Board. If any nominee were to become unavailable to serve as a director, our Board may designate a substitute nominee. In that case, the persons named as proxies on the accompanying proxy card will vote for the substitute nominee designated by our Board.

**Bruce Horowitz**, 62, since April 2017, has served as the Chief Operations Consultant and member of the Board of Directors of Provectus Biopharmaceuticals, Inc. Mr. Horowitz has served as the Managing Director of Capital Strategists, LLC, which provides corporate, strategic, and financial consulting services, since September 2006. He also serves as a trusted advisor to family trusts and private individuals, with a focus on financial asset management, real estate management and special situation investments. He has also served as the Managing Member of Plata LLC since 2017. Earlier in his career Mr. Horowitz was a charter member of the New York Futures Exchange, a Senior Vice President managing principal equity investment accounts, private equity investments and public offerings at Drake Capital Securities, and managed the trading department at Laidlaw Equities. He was also a partner at Stanley Capital, a private equity buyout firm. Mr. Horowitz was the chairman and a member of two general obligation bond fund committees, raising more than \$500 million in general revenue bonds for the Beverly Hills Unified School District. Subsequently, he was named the first chairman of both the state of California-mandated Citizens' Oversight Committee and Facilities Advisory Committee, overseeing expenditure of all BHUSD general obligation bond funds. Mr. Horowitz is a founding member of the Los Angeles Chapter of the Positive Coaching Alliance. He founded and is currently the president of the Beverly Hills Basketball League, a youth basketball program that serves more than 35,000 families. Mr. Horowitz has also served as a member of the board of directors of the American Youth Soccer Organization and Beverly Hills Little League. He holds a Juris Doctor degree from Benjamin N. Cardozo School of Law in New York City and Bachelor of Arts degree from Washington University in St. Louis.

**Jan Koe**, 67, has served as a member of our board of directors since May 14, 2012. Mr. Koe has a 31-year track record of success in consulting, asset management, real estate and public company governance, and has represented major insurance firms, national retailers and Fortune 500 companies. He is President of GoStar, which is the manager of Real Solutions Opportunity Fund 2005-I and Real Solutions Fund Management LLC and Real Solutions Investment LLC. He is also Principal of Method K Partners, Inc., a commercial real estate firm, which he founded in 1988. He has served on the board of directors of ONE Bio, Corp. where he was Chair of the Compensation Committee and a member of the Financial Audit Committee. He holds a degree in Business Administration and Psychology from Luther College.

**John Lacey, III, M.D.**, 70, is the former Chief Medical Officer and Senior Vice President of University Health System d/b/a University of Tennessee Medical Center (“UTMC”), a 600+ bed academic medical center based in Knoxville since 1999. Dr. Lacey served continuously in this capacity from 1999 until retirement from UTMC in 2016. He also operated an internal medicine practice for 39 years. Dr. Lacey graduated from the University of Tennessee with a Bachelor’s degree in Nuclear Engineering and the University of Tennessee Medical School (Memphis) with a Doctor of Medicine degree. Dr. Lacey helped create Knoxville Area Project Access, a partnership with the Knoxville Academy of Medicine and providers to give primary and specialty health services to the uninsured and medically underserved, and was the inaugural chair of the Governor’s Health and Wellness Task Force, which focused on improving Tennessee’s national health ranking. Dr. Lacey has been recognized by several entities for contributions to population health.

**Ed Pershing, CPA**, 65, is Chief Executive Officer of Pershing Yoakley & Associates (“PYA”), a top 20 healthcare consulting and top 100 accounting firm in the U.S. PYA, which he co-founded more than 30 years ago, expanded from a three-employee office to more than 270 employees and five affiliate companies serving more than 3,500 clients in 50 states. Mr. Pershing’s healthcare experience and expertise include turnaround/performance improvement initiatives, long-range planning studies, development of numerous hospital and medical office projects, restructuring of healthcare organizations, liaison between boards of directors and management teams to craft corporate visions and strategies, mergers, acquisitions, divestitures, and leasing arrangements. He has served as an expert witness on healthcare industry matters and in several Certificate of Need appeals. Mr. Pershing also has represented healthcare organizations before regulatory agencies such as the Centers for Medicare & Medicaid Services, Internal Revenue Service, and Departments of Mental Health, Insurance, and Medicaid. He graduated from the University of Tennessee with a Bachelor of Science in Accounting, and was one of 18 professionals from the U.S. and Great Britain to participate in the first Ernst & Ernst Accelerated Healthcare Program, a one-year full-time education and work-study program in healthcare industry matters. Mr. Pershing is a Certified Professional Accountant.

**Dominic Rodrigues, CFA**, 49, has served in a leadership role at Provectus since 2017. Mr. Rodrigues previously served as President of Rhisk Capital, which provided management consulting, corporate development, and portfolio management services, since 2005. Project industries and technologies included aerospace & defense (a technology-focused investment capital pool; an operational role in a related data communications solutions company), biotechnology, financial services (a capital markets-focused technology company), gaming, healthcare, life sciences, nanotechnology (a venture capital fund investment), wealth management (a start-up private wealth office), and restaurants. Since 2013 Mr. Rodrigues has been an Adjunct Professor of Finance at the Lee Business School of the University of Nevada, Las Vegas, where he teaches valuation and CFA exam preparation courses. His business development, corporate development, finance, and leadership experiences at various companies include SAIC Venture Capital Corporation, the multi-billion dollar subsidiary of research and engineering company SAIC, where he was an observer or member of the board of directors of 11 different firms. Mr. Rodrigues currently serves as a member of the audit & finance committee of Three Square Food Bank. He holds business, economics, and engineering degrees from The Wharton School, the London School of Economics, the Massachusetts Institute of Technology, and the University of Toronto. Mr. Rodrigues also is a Chartered Financial Analyst.

#### Experience, Qualifications, Attributes and Skills of Our Director Nominees

Set forth below are the specific experience, qualifications, attributes and skills of our directors that led to the conclusion that each director should serve as a member of our Board.

**Jan Koe** brings extensive and diverse board of directors and board committee, chief executive, and leadership experience to our board of directors and company management from his prior and ongoing work, and educational background.

**Bruce Horowitz** brings extensive and diverse board of directors, business development, corporate development, strategic planning, capital formation, and leadership experience to our board of directors and company management from his prior and ongoing work, non-profit volunteerism, and educational background.

**Ed Pershing, CPA** brings extensive and diverse board of directors, business development, corporate development, strategic planning, accounting, healthcare industry, and leadership experience to our Board and company management from his prior and ongoing work, non-profit volunteerism, and educational background.

**John Lacey, III, M.D.** brings extensive and diverse board of directors, medical, strategic planning, and leadership experience to our Board and company management from his prior work, non-profit volunteerism, and educational background.

**Dominic Rodrigues, CFA** brings extensive and diverse board of directors and board committee, business development, corporate development, finance, and leadership experience to our board of directors and company management from his prior and ongoing work and professional volunteerism, and educational background.

**OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” EACH OF THE NOMINEES FOR ELECTION TO OUR BOARD NAMED ABOVE.** Each proxy solicited on behalf of our Board will be voted *FOR* each of the nominees for election to our Board unless the stockholder instructs otherwise in the proxy.



PROPOSAL 2

ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

As required pursuant to Section 14A of the Securities Exchange Act, we are submitting for stockholder advisory vote a resolution to approve the compensation paid to our named executive officers, as disclosed pursuant to the compensation disclosure rules of the SEC.

Accordingly, the following resolution will be submitted for stockholder approval at the Annual Meeting:

“RESOLVED, that the compensation paid to the Company’s named executive officers, as disclosed in this Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission, is hereby APPROVED.”

The advisory vote on the compensation of our named executive officers is non-binding. The approval or disapproval of the resolution approving our executive compensation by our stockholders will not require our Board to take any action regarding our executive compensation practices. The final decision on the compensation and benefits of our named executive officers and whether, and if so, how, to address stockholder disapproval remains with our Board.

Our Board believes that it is in the best position to consider the extensive information and factors necessary to make independent, objective, and competitive compensation recommendations and decisions that are in our best interest and the best interest of our stockholders.

Our Board values the opinions of our stockholders as expressed through their votes and other communications. Although the resolution is non-binding, our Board will carefully consider the outcome of the advisory vote to approve the compensation of our named executive officers and those opinions when making future compensation decisions.

The next advisory vote on the compensation of our executive officers will occur at the 2019 Annual Meeting of Stockholders.

**OUR BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE *FOR* THE APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.** Each proxy solicited on behalf of our Board

will be voted *FOR* the approval of the compensation of our named executive officers unless the stockholder instructs otherwise in the proxy.

### PROPOSAL 3

#### RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

##### General

Each of our audit committee and Board has unanimously selected Marcum LLP as the independent registered public accounting firm to perform the audit of our consolidated financial statements for 2018. Marcum LLP is an independent registered public accounting firm.

Our Board is asking our stockholders to ratify the selection of Marcum LLP as our independent registered public accounting firm for 2018. Although not required by law or our bylaws, our Board is submitting the selection of Marcum LLP to our stockholders for ratification as a matter of good corporate practice. Even if the selection is ratified, our Board, in its discretion, may select a different registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of us and our stockholders.

##### Previous Independent Registered Public Accounting Firm

During and for the fiscal years ended December 31, 2015 and 2014, BDO USA, LLP audited and rendered opinions on the financial statements of the Company and its subsidiaries. BDO USA, LLP also rendered opinions on the Company's internal control over financial reporting as of December 31, 2015 and 2014.

On April 26, 2016, the Company notified its independent registered public accounting firm, BDO USA, LLP, of its decision to dismiss BDO USA, LLP, effective as of that date, and to appoint another independent registered public accounting firm, Marcum LLP. The decision to change independent registered public accounting firms was unanimously approved by the Company's audit committee and board of directors.

BDO USA, LLP's reports on the consolidated financial statements of the Company for the fiscal years ended December 31, 2015 and 2014, did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principle.

During the fiscal years ended December 31, 2015 and 2014, and the subsequent interim period through April 26, 2016, the date of BDO USA, LLP's dismissal, there were no "disagreements" (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) with BDO USA, LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of BDO USA, LLP, would have caused BDO USA, LLP to make reference to the subject matter of the disagreements in connection with its reports on the Company's consolidated financial statements for such periods.

During the fiscal years ended December 31, 2015 and 2014, and the subsequent interim period through April 26, 2016, there were no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K), other than the identification of a material weakness in the Company's internal control over financial reporting as described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the "2015 Form 10-K"). As disclosed in Item 9A to the 2015 Form 10-K, the Company's principal executive officer and principal financial officer concluded that, as of December 31, 2015, the Company's internal control over financial reporting was not effective due to a material weakness related to the Company's travel expense advancement and reimbursement policies and procedures that relate to the Company's former Chief Executive Officer and Chairman of the board of directors, H. Craig Dees, Ph.D. BDO USA, LLP's audit report included in the 2015 10-K with respect to the Company's internal control over financial reporting opined that the Company did not maintain effective internal control over financial reporting as of December 31, 2015 because of this material weakness. The subject matter of this material weakness was discussed by the Company's audit committee with BDO USA, LLP. The audit committee has authorized BDO USA, LLP to respond fully to the inquiries of the successor independent registered public accounting firm concerning this material weakness.

The Company has provided BDO USA, LLP with a copy of the foregoing disclosures and requested that BDO USA, LLP furnish the Company with a letter addressed to the SEC stating whether or not it agrees with the statements in the above paragraphs. A copy of BDO USA, LLP's letter was attached as Exhibit 16.1 to the Company's Current Report on Form 8-K filed with the SEC on April 29, 2016.

#### Current Independent Registered Public Accounting Firm

On April 26, 2016, the Company engaged Marcum LLP as its independent registered public accounting firm. The decision to engage Marcum LLP as the Company's independent registered public accounting firm was unanimously approved by the Company's audit committee and Board. During the year ended December 31, 2015, and through April 26, 2016, the date of Marcum LLP's engagement, the Company did not consult with Marcum LLP regarding any of the matters or events set forth in Item 304(a)(2)(i) and (ii) of Regulation S-K.

Representatives of Marcum LLP are expected to be present at the Annual Meeting telephonically. They will have an opportunity to make a statement if they desire and will be available to respond to appropriate questions from our stockholders.

**OUR BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE *FOR* THE RATIFICATION OF THE SELECTION OF MARCUM LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2018.** Each proxy solicited on behalf of our Board will be voted *FOR* the ratification of the selection of Marcum LLP as our independent registered public accounting firm for 2018 unless the stockholder instructs otherwise in the proxy. If our stockholders do not ratify the selection, the matter will be reconsidered by our Board.

#### Audit and Non-Audit Services

Our audit committee is directly responsible for the appointment, compensation, and oversight of our independent registered public accounting firm. It is the policy of our audit committee to pre-approve all audit and non-audit services provided by our independent registered public accountants. Our audit committee has considered whether the provision by Marcum LLP of services of the varieties described below was compatible with maintaining the independence of Marcum LLP. Our audit committee believes the provision of such services to us did not jeopardize the independence of Marcum LLP as the Company's independent registered public accounting firm.

The table below sets forth the aggregate fees we paid to Marcum LLP for audit and non-audit services provided to us in 2017 and 2016:

Fees	2017	2016
Audit Fees	\$192,954	\$326,638
Audit-Related Fees	—	—
Tax Fees	—	—
All Other Fees	—	—
Total	\$192,954	\$326,638

In the above table, in accordance with the SEC's definitions and rules, "audit fees" are fees for professional services for the audit of a company's financial statements included in the annual report on Form 10-K, for the review of a company's financial statements included in the quarterly reports on Form 10-Q, and for services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements; "audit-related fees" are fees for assurance and related services that are reasonably related to the performance of the audit or review of a company's financial statements; "tax fees" are fees for tax compliance, tax advice, and tax planning; and "all other fees" are fees for any services not included in the first three categories.

## AUDIT COMMITTEE REPORT

Our audit committee has the responsibilities and powers set forth in its charter, which include the responsibility to assist our Board in its oversight of our accounting and financial reporting principles and policies and internal audit controls and procedures, the integrity of our financial statements, our compliance with legal and regulatory requirements, the independent registered public accounting firm's qualifications and independence, and the performance of the independent registered public accounting firm and our internal audit function. The audit committee is also required to prepare this report to be included in our annual Proxy Statement pursuant to the proxy rules of the SEC.

Management is responsible for the preparation, presentation and integrity of our financial statements and for maintaining appropriate accounting and financial reporting principles and policies and internal controls and procedures to provide for compliance with accounting standards and applicable laws and regulations. The internal auditor is responsible for testing such internal controls and procedures. Our independent registered public accounting firm is responsible for planning and carrying out a proper audit of our annual financial statements, reviews of our quarterly financial statements prior to the filing of each quarterly report on Form 10-Q, and other procedures.

The audit committee reviews our financial reporting process. In this context, the audit committee:

reviewed and discussed with management the audited financial statements for the year ended December 31, 2017;

discussed with Marcum LLP, our independent registered public accountants, the matters required to be discussed under the rules adopted by the Public Company Accounting Oversight Board (the "PCAOB"); and

received the written disclosures and the letter from Marcum LLP required by the PCAOB, and has discussed with Marcum LLP the independent accountant's independence.

Based on this review and the discussions referred to above, the audit committee recommended that our Board include the audited financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017, for filing with the SEC.



This report is submitted on behalf of the members of the audit committee, who are named below, and shall not be deemed “soliciting material” or to be “filed” with the SEC, nor shall it be incorporated by any general statement incorporating by reference this Proxy Statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate this information by reference and shall not otherwise be deemed filed under these Acts.

Bruce Horowitz

Jan Koe

John Lacey, III, M.D.

Ed Pershing, CPA

Dominic Rodrigues, CFA

#### OTHER INFORMATION CONCERNING MANAGEMENT

##### Executive Officers

**Bruce Horowitz** serves as our Chief Operations Consultant. Information about his business experience is set forth above under the heading, “Proposal 1 – ELECTION OF DIRECTORS – Director Nominees.”

**Timothy C. Scott, Ph.D.**, 60, serves as our President since April 23, 2002. Dr. Scott previously served as a member of our board of directors from April 23, 2002 until April 3, 2017. Prior to joining us, Dr. Scott was a senior member of the Photogen management team from 1997 to 2002, including serving as Photogen’s Chief Operating Officer from 1999 to 2002, as a director of Photogen from 1997 to 2000, and as interim CEO for a period in 2000. Before joining Photogen, he served as senior management of Genase LLC, a developer of enzymes for fabric treatment and held senior research and management positions at Oak Ridge National Laboratory. Dr. Scott earned a Ph.D. in Chemical Engineering from the University of Wisconsin–Madison in 1985.

**John Glass, CPA**, 74, serves as our Interim Chief Financial Officer (since April 18, 2016). Mr. Glass is the President of J.R. Glass & Associates, a consulting firm he founded in 1990 to assist clients in the financial, operational and marketing segments of their business. In this role, his responsibilities have included, among others, preparation of periodic reports to be filed with the Securities and Exchange Commission and Sarbanes-Oxley compliance

documentation. From January 2007 to May 2014, Mr. Glass served as controller for CytoCore, Inc. (OTCBB: CYOE) (now known as Medite Cancer Diagnostics Inc.), a late development stage bio molecular diagnostics company. His prior chief financial officer experience includes serving as Chief Financial Officer of U. S. RealTel, Inc., a publicly traded company in the telecommunications industry, Vice President and Chief Financial Officer of Health Charge Corporation, a financial services company in the health care industry, and Vice President and Chief Financial Officer of Aluminum Distributors, Inc., a metal processor and distributor. He also previously served as Vice President of Fulton Manufacturing Industries, Inc. and as a Manager at Grant Thornton LLP, a registered public accounting firm. Mr. Glass is chairman of the Plan Commission of Elk Grove Village, a member of the Illinois CPA Society and past chairman and member of the Board for the Greater O'Hare Service Corporation. He received his B.B.A. in Accounting from Loyola University.

**Eric A. Wachter, Ph.D.**, 54, serves as our Chief Technology Officer since May 14, 2012. Dr. Wachter previously served as Executive Vice President – Pharmaceuticals and as a member of our Board since we acquired PPI on April 23, 2002 until May 14, 2012 and again from February 29, 2016 to April 27, 2018. Prior to joining us, from 1997 to 2002 he was a senior member of the management team of Photogen, including serving as Secretary and a director of Photogen since 1997 and as Vice President and Secretary and a director of Photogen since 1999. Prior to joining Photogen, Dr. Wachter served as a senior research staff member with Oak Ridge National Laboratory. He earned a Ph.D. in Chemistry from the University of Wisconsin–Madison in 1988.

#### Code of Ethics

Our Board has adopted a code of ethics that applies to our principal executive officer and principal financial officer, or persons performing similar functions. The code of ethics contains written standards that are reasonably designed to deter wrongdoing and to promote: (1) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (2) full, fair, accurate, timely, and understandable disclosure in reports and documents that we file with, or submit to, the SEC and in other public communications made by us; (3) compliance with applicable governmental laws, rules and regulations; (4) the prompt internal reporting of violations of the code to an appropriate person or persons identified in the code; and (5) accountability for adherence to the code. The code of ethics is available without charge upon request from our Secretary, Provectus Biopharmaceuticals, Inc., 10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932.

#### OTHER MATTERS

As of the date hereof, our Board knows of no business that will be presented at the meeting other than the proposals described in this Proxy Statement. If any other proposal properly comes before the stockholders for a vote at the meeting, the proxy holders will vote the shares of common stock represented by proxies that are submitted to us in accordance with their best judgment.

## ADDITIONAL INFORMATION

### Solicitation of Proxies

We will solicit proxies on behalf of our Board by mail, telephone, facsimile, or other electronic means or in person. We will pay the proxy solicitation costs. We will supply copies of the proxy solicitation materials to brokerage firms, banks, and other nominees for the purpose of soliciting proxies from the beneficial owners of the shares of common stock held of record by such nominees. We request that such brokerage firms, banks, and other nominees forward the proxy solicitation materials to the beneficial owners, and we will reimburse them for their reasonable expenses.

### Mailing Address of Principal Executive Office

The mailing address of our principal executive office is Provectus Biopharmaceuticals, Inc., 10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932.

### Stockholder Proposals for Inclusion in Proxy Statement for 2019 Annual Meeting of Stockholders

To be considered for inclusion in our proxy statement for the 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”), a stockholder proposal must be received by us no later than the close of business on December 28, 2018. Stockholder proposals must be sent to Secretary, Provectus Biopharmaceuticals, Inc., 10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932. We will not be required to include in our proxy statement any stockholder proposal that does not meet all the requirements for such inclusion established by the SEC’s proxy rules and Delaware corporate law.

### Other Stockholder Proposals for Presentation at the 2019 Annual Meeting

In addition to the above, our bylaws contain an advance notice provision requiring that, if a stockholder’s proposal is to be brought before and considered at the 2019 Annual Meeting, such stockholder must provide timely written notice thereof to our Secretary. In order to be timely, the notice must be delivered to or mailed and received by our Secretary at our principal executive offices not earlier than the close of business on December 28, 2018 and not later than the close of business on January 27, 2019; provided, however, that in the event the date of the 2019 Annual Meeting is

more than 30 days before or more than 30 days after the anniversary of the 2018 Annual Meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 90th day prior to the date of such 2019 Annual Meeting and not later than the close of business on the later of the 60th day prior to the date of such 2019 Annual Meeting or the 10th day following the day on which public announcement of the date of such annual meeting is first made by us. In the event a stockholder proposal intended to be presented for action at the 2019 Annual Meeting is not received timely, then the persons designated as proxies in the proxies solicited by the Board in connection with the 2019 Annual Meeting will be permitted to use their discretionary voting authority with respect to the proposal, whether or not the proposal is discussed in the proxy statement for the 2019 Annual Meeting.

**By Order of our Board**

Knoxville, Tennessee **Timothy C. Scott, Ph.D.**  
April 30, 2018 *President*





